586 related articles for article (PubMed ID: 29411994)
1. Anticancer metallodrugs: where is the next cisplatin?
Hanif M; Hartinger CG
Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
[TBL] [Abstract][Full Text] [Related]
2. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
Lazarević T; Rilak A; Bugarčić ŽD
Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
[TBL] [Abstract][Full Text] [Related]
3. Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Kenny RG; Marmion CJ
Chem Rev; 2019 Jan; 119(2):1058-1137. PubMed ID: 30640441
[TBL] [Abstract][Full Text] [Related]
4. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
5. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
6. Stimuli-Responsive Therapeutic Metallodrugs.
Wang X; Wang X; Jin S; Muhammad N; Guo Z
Chem Rev; 2019 Jan; 119(2):1138-1192. PubMed ID: 30299085
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic Drugs and Plasma Proteins: Exploring New Dimensions.
Zia MK; Siddiqui T; Ali SS; Rehman AA; Ahsan H; Khan FH
Curr Protein Pept Sci; 2018; 19(10):937-947. PubMed ID: 28969563
[TBL] [Abstract][Full Text] [Related]
8. A safe and efficacious Pt(ii) anticancer prodrug: design, synthesis, in vitro efficacy, the role of carrier ligands and in vivo tumour growth inhibition.
Dutta PK; Sharma R; Kumari S; Dubey RD; Sarkar S; Paulraj J; Vijaykumar G; Pandey M; Sravanti L; Samarla M; Das HS; Yashpal ; B H; Goyal R; Gupta N; Mandal SK; Sengupta A; Sarkar A
Chem Commun (Camb); 2019 Feb; 55(12):1718-1721. PubMed ID: 30623966
[TBL] [Abstract][Full Text] [Related]
9. Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy.
Liu J; Lai H; Xiong Z; Chen B; Chen T
Chem Commun (Camb); 2019 Aug; 55(67):9904-9914. PubMed ID: 31360938
[TBL] [Abstract][Full Text] [Related]
10. Anticancer metallotherapeutics in preclinical development.
Kaluderović GN; Paschke R
Curr Med Chem; 2011; 18(31):4738-52. PubMed ID: 21919843
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy.
Zhang X; Liu D; Lv F; Yu B; Shen Y; Cong H
Colloids Surf B Biointerfaces; 2019 Oct; 182():110373. PubMed ID: 31376689
[TBL] [Abstract][Full Text] [Related]
12. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis.
Ma L; Ma R; Wang Z; Yiu SM; Zhu G
Chem Commun (Camb); 2016 Sep; 52(71):10735-8. PubMed ID: 27506281
[TBL] [Abstract][Full Text] [Related]
13. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy.
Abid M; Shamsi F; Azam A
Mini Rev Med Chem; 2016; 16(10):772-86. PubMed ID: 26423699
[TBL] [Abstract][Full Text] [Related]
14. Noble metal-dithiocarbamates precious allies in the fight against cancer.
Nagy EM; Ronconi L; Nardon C; Fregona D
Mini Rev Med Chem; 2012 Oct; 12(12):1216-29. PubMed ID: 22931593
[TBL] [Abstract][Full Text] [Related]
15. Development of anticancer agents: wizardry with osmium.
Hanif M; Babak MV; Hartinger CG
Drug Discov Today; 2014 Oct; 19(10):1640-8. PubMed ID: 24955838
[TBL] [Abstract][Full Text] [Related]
16. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
17. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
Deng Z; Zhu G
Curr Opin Chem Biol; 2023 Jun; 74():102303. PubMed ID: 37075513
[TBL] [Abstract][Full Text] [Related]
18. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.
van Rijt SH; Sadler PJ
Drug Discov Today; 2009 Dec; 14(23-24):1089-97. PubMed ID: 19782150
[TBL] [Abstract][Full Text] [Related]
19. Metal Complexes in Cancer Treatment: Journey So Far.
Kumar Singh A; Kumar A; Singh H; Sonawane P; Pathak P; Grishina M; Pal Yadav J; Verma A; Kumar P
Chem Biodivers; 2023 Apr; 20(4):e202300061. PubMed ID: 36824028
[TBL] [Abstract][Full Text] [Related]
20. Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology?
Nardon C; Brustolin L; Fregona D
Future Med Chem; 2016; 8(2):211-26. PubMed ID: 26807601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
